2020
Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses
Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. The BMJ 2020, 368: l7078. PMID: 32024657, PMCID: PMC7190063, DOI: 10.1136/bmj.l7078.Peer-Reviewed Original ResearchMeSH KeywordsCardiovascular DiseasesHumansHypoglycemic AgentsInformation DisseminationRandomized Controlled Trials as TopicRisk FactorsRosiglitazoneConceptsIndividual patient-level dataCardiovascular related deathsCardiovascular riskMyocardial infarctionRelated deathsSummary-level dataHeart failureOdds ratioSystematic reviewIncreased cardiovascular riskMore myocardial infarctionsHeart failure eventsCochrane Central RegistryAcute myocardial infarctionMyocardial infarction eventsPatient-level dataRandom-effects modelWeb of ScienceAnalysis of trialsEligible trialsComposite outcomeAdverse eventsContinuity correctionControlled TrialsRosiglitazone treatment
2012
Active Transportation and Cardiovascular Disease Risk Factors in U.S. Adults
Furie GL, Desai MM. Active Transportation and Cardiovascular Disease Risk Factors in U.S. Adults. American Journal Of Preventive Medicine 2012, 43: 621-628. PMID: 23159257, DOI: 10.1016/j.amepre.2012.06.034.Peer-Reviewed Original ResearchConceptsCardiovascular disease risk factorsDisease risk factorsRisk factorsPhysical activityFavorable cardiovascular risk factor profileCardiovascular risk factor profileHigh-density lipoprotein levelsU.S. adultsOdds of hypertensionRisk factor profileActive transportationNutrition Examination SurveyMinutes/weekLogistic regression analysisTransportation physical activityEvidence of associationWaist circumferenceLipoprotein levelsSmoking statusExamination SurveyNational HealthLower oddsHealth outcomesFactor profileSociodemographic characteristics
2009
From Here to JUPITER
Spatz ES, Canavan ME, Desai MM. From Here to JUPITER. Circulation Cardiovascular Quality And Outcomes 2009, 2: 41-48. PMID: 20031811, DOI: 10.1161/circoutcomes.108.832592.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersCardiovascular DiseasesC-Reactive ProteinEvidence-Based MedicineFemaleHealth SurveysHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInflammation MediatorsLipoproteins, LDLMaleMiddle AgedNutrition SurveysPatient SelectionPractice Guidelines as TopicRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsTime FactorsConceptsHigh-sensitivity C-reactive proteinLow-density lipoproteinStatin therapyC-reactive proteinElevated high-sensitivity C-reactive protein levelsHigh-sensitivity C-reactive protein levelsElevated low-density lipoprotein levelsGoal low-density lipoproteinIntervention Trial Evaluating RosuvastatinC-reactive protein levelsOlder personsLow-density lipoprotein levelsUse of statinsNutrition Examination SurveyCardiovascular riskMetabolic syndromeLipoprotein levelsPrimary preventionExamination SurveyTreatment recommendationsNational HealthElderly adultsTherapyStatinsOlder adults